<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394341</url>
  </required_header>
  <id_info>
    <org_study_id>H-3-2011-032</org_study_id>
    <secondary_id>2010-021922-36</secondary_id>
    <nct_id>NCT01394341</nct_id>
  </id_info>
  <brief_title>Liraglutide Treatment to Patients With Severe Renal Insufficiency</brief_title>
  <official_title>Safety and Effect of Liraglutide in Patients With Type 2 Diabetes and Severe Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bo Feldt-Rasmussen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The GCP unit at Copenhagen University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Incretin-based therapy for the treatment of patients with type 2 diabetes mellitus (T2D) is&#xD;
      new and fundamentally different from the classical treatments with oral antidiabetic agents&#xD;
      and insulin. The novel and original aspect of this investigator-initiated study is the focus&#xD;
      on treatment with an incretin-based agent (the GLP-1 analogue liraglutide) in T2D patients&#xD;
      with severely reduced kidney function. At present there is virtually no knowledge of the&#xD;
      physiology and clinical implications of the role of incretin hormones and incretin-based&#xD;
      therapy in this group of diabetic patients.The aim of the study is to establish an&#xD;
      evidence-based rationale for introducing a GLP-1 analogue to the limited armamentarium of&#xD;
      antidiabetic drugs for patients with type T2D and severe renal insufficiency. The overall&#xD;
      hypothesis is that patients with T2D and severe renal insufficiency will tolerate and benefit&#xD;
      from treatment with the GLP-1 analogue liraglutide, hereby improving glycaemic control and&#xD;
      reducing risk factors of cardiovascular disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma liraglutide concentration (pmol/L)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma liraglutide concentration evaluated over time during continuous intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemia; minor or major</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of hypoglycaemic episodes during intervention. Minor (blood glucose &lt;3.1 mmol/L, no need for assistance). Major (blood glucose &lt;3.1 mmol/L, assistance from third person required)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycaemic control</measure>
    <time_frame>12 weeka</time_frame>
    <description>Glycaemic control evaluated from 3 daily measurements of blood glucose, from 4 periods of 24-hour tissue glucose measurements (5 days each) and from HbA1c during the intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic beta-cell function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pancreatic beta-cell function evaluated from insulin- and C-peptide-secretion during a standard meal test 3 times during the intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors (lipids and blood pressure)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood pressure will be evaluated at each visit and lipid profile (HDL, LDL, total cholesterol and triglyceride) 3 times during the intervention period.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>T2D, Dialysis, Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily liraglutide treatment Chronic dialysis treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D, Dialysis, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily placebo Chronic dialysis treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D, Normal kidney function, Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily Liraglutide treatment Normal kidney function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D, Normal kidney function, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily placebo treatment Normal kidney function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Daily sc. injection, individual dosage</description>
    <arm_group_label>T2D, Dialysis, Liraglutide</arm_group_label>
    <arm_group_label>T2D, Dialysis, Placebo</arm_group_label>
    <arm_group_label>T2D, Normal kidney function, Liraglutide</arm_group_label>
    <arm_group_label>T2D, Normal kidney function, Placebo</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria - patients with T2D in dialysis&#xD;
&#xD;
          -  Male or female; aged 18-85 years&#xD;
&#xD;
          -  End-stage renal disease&#xD;
&#xD;
          -  Chronic dialysis treatment (minimum 3 months)&#xD;
&#xD;
          -  T2D (diagnosed according to WHO criteria)&#xD;
&#xD;
          -  Treated with diet/lifestyle intervention, oral antidiabetic drugs (SU, glitazones)&#xD;
             and/or insulin&#xD;
&#xD;
          -  Documented beta cell function (evaluated by a glucagon test)&#xD;
&#xD;
        Inclusion criteria - patients with T2D and normal kidney function&#xD;
&#xD;
          -  Male or female; aged 18-85 years&#xD;
&#xD;
          -  Normal kidney function: Plasma creatinine &lt;0.105 mmol/L for men and &lt;0.090 mmol/L for&#xD;
             women&#xD;
&#xD;
          -  T2D (diagnosed according to WHO criteria)&#xD;
&#xD;
          -  Treated with diet/lifestyle intervention, oral antidiabetic drugs (SU, glitazones)&#xD;
             and/or insulin&#xD;
&#xD;
          -  Documented beta cell function (evaluated by a glucagon test)&#xD;
&#xD;
          -  Hemoglobin A1c ≥6.5%&#xD;
&#xD;
        Exclusion Criteria - both groups&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Chronic pancreatitis / previous acute pancreatitis&#xD;
&#xD;
          -  Known or suspected hypersensitivity to trial product(s) or related products&#xD;
&#xD;
          -  Treatment with oral glucocorticoids, calcineurin inhibitors, dipeptidyl peptidase 4&#xD;
             (DPP4) inhibitors or other drugs, which in the Investigator's opinion could interfere&#xD;
             with glucose or lipid metabolism 90 days prior to screening&#xD;
&#xD;
          -  Cancer (except basal cell skin cancer or squamous cell skin cancer) or any other&#xD;
             clinically significant disorder which in the investigators' opinion could interfere&#xD;
             with the results of the trial&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Cardiac disease defined as: decompensated heart failure (NYHA class III-IV) and/or&#xD;
             diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6&#xD;
             months&#xD;
&#xD;
          -  Body mass index ≤ 18.5 kg/m2 or ≥ 50.0 kg/m2&#xD;
&#xD;
          -  Females of childbearing potential who are pregnant, breast-feeding, intend to become&#xD;
             pregnant or are not using adequate contraceptive methods&#xD;
&#xD;
          -  Clinical signs of diabetic gastroparesis&#xD;
&#xD;
          -  Impaired liver function (transaminases &gt;two times upper reference levels)&#xD;
&#xD;
          -  Receipt of any investigational product 90 days prior to this trial&#xD;
&#xD;
          -  Known or suspected abuse of alcohol or narcotics&#xD;
&#xD;
          -  Screening calcitonin ≥50 ng/l&#xD;
&#xD;
          -  Subjects with personal or family history of medullary thyroid carcinoma or a personal&#xD;
             history of multiple endocrine neoplasia type 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Feldt-Rasmussen, Prof, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of Nephrology P, Copenhagen University Hospital, Rigshospitalet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Idorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology P, Copenhagen University Hospital, Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology PE, Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen Ø</city>
        <state>Copenhagen</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology P, Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen Ø</city>
        <state>Copenhagen</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine H, Hillerød Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2011</study_first_posted>
  <last_update_submitted>October 8, 2013</last_update_submitted>
  <last_update_submitted_qc>October 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Bo Feldt-Rasmussen</investigator_full_name>
    <investigator_title>Professor, DMSc, Head of Department</investigator_title>
  </responsible_party>
  <keyword>Liraglutide</keyword>
  <keyword>Uremia</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

